Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 30, 2022

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions
Alcoholism
Interventions
DRUG

Ibogaine Hydrochloride

The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.

Trial Locations (1)

14048900

Ribeirão Preto Medical School, Ribeirão Preto

All Listed Sponsors
collaborator

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

OTHER_GOV

collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico

OTHER_GOV

collaborator

International Center for Ethnobotanical Education, Research, and Service

OTHER

lead

University of Sao Paulo

OTHER